The therapeutic community is abuzz with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 agonist that’s showing significant potential in clinical trials for treating obesity. Unlike some current weight loss treatments, retatrutide appears to deliver a greater substantial decr